Qualitative Concept
Cardurion Pharmaceuticals Raises $260M in Series B Funding to Challenge Statin-Dominated Cardiovascular Market
Cardurion Pharmaceuticals, Series B Funding, Cardiovascular, Statins, Biotech, Bain Capital, Ascenta Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures
FDA Rejects Novo Nordisk’s Once-Weekly Insulin Icodec for Diabetes Treatment
FDA, Novo Nordisk, Icodec, Weekly Insulin, Diabetes Treatment, Type 1 Diabetes, Type 2 Diabetes, Complete Response Letter
Almirall’s Ebglyss Gains NICE Recommendation for Atopic Dermatitis Treatment
Ebglyss, lebrikizumab, atopic dermatitis, NICE recommendation, Almirall, NHS England, biological therapy, moderate to severe atopic dermatitis
How the world’s biggest pharma and biotech companies paid their typical worker in 2023
Midline (qualifier value), Wages, Pharma, Worker
How the world’s biggest pharma and biotech companies paid their typical worker in 2023
2023, Midline (qualifier value), Gilead, Wages, Average, Highest
How the world’s biggest pharma and biotech companies paid their typical worker in 2023
Dosage Forms, Industry, world ‘s, Worker, 2023
Arcutis Biotherapeutics Secures FDA Approval for ZORYVE Cream to Treat Atopic Dermatitis
Arcutis Biotherapeutics, ZORYVE, Atopic Dermatitis, FDA Approval, Roflumilast Cream, Steroid-Free Treatment
UniQure Wins First FDA RMAT in Huntington’s Disease After Strong Phase I/II Data
UniQure, Huntington’s disease, gene therapy, AMT-130, FDA, RMAT designation, Phase I/II clinical trials, neurodegenerative disorder, neurofilament light (NfL), disease progression, composite Unified Huntington’s Disease Rating Scale (cUHDRS).
FDA Approves Eli Lilly’s Alzheimer’s Drug Donanemab, Offering New Treatment Option
Alzheimer’s disease, Eli Lilly, FDA approval, donanemab, Kisunla, anti-amyloid monoclonal antibody, cognitive decline, amyloid plaques, treatment options